DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2015/0064124 A1 YONTZ Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2015/0064124 A1 YONTZ Et Al US 2015 0064124A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0064124 A1 YONTZ et al. (43) Pub. Date: Mar. 5, 2015 (54) PERSONAL CARE FORMULATIONS A61O 9/04 (2006.01) CONTAINING ALKYL KETAL ESTERS AND A618/34 (2006.01) METHODS OF MANUFACTURE A61O5/10 (2006.01) A61O 1/02 (2006.01) (71) Applicants: Dorie J. YONTZ, Bloomington, MN A647/22 (2006.01) (US); Lee Richard RIETH, Plymouth, AOIN 25/00 (2006.01) MN (US); Nicholas MORANTE, A61O 1704 (2006.01) Holbrook, NY (US): Irwin PALEFSKY, A6R8/97 (2006.01) Fairfield, NJ (US) (52) U.S. Cl. CPC ................ A61K 8/498 (2013.01); A61O 1704 (72) Inventors: Dorie J. YONTZ, Bloomington, MN (2013.01); A61O 15/00 (2013.01); A61 K (US); Lee Richard RIETH, Plymouth, 8/4973 (2013.01); A61K 8/35 (2013.01); A61 K MN (US); Nicholas MORANTE, 8/368 (2013.01); A61K 8/97 (2013.01); A61 K Holbrook, NY (US): Irwin PALEFSKY, 8/34 (2013.01); A61K 8/4953 (2013.01); A61O Fairfield, NJ (US) 5/10 (2013.01); A61O 1/02 (2013.01); A61 K 47/22 (2013.01); A0IN 25/00 (2013.01); A61O (73) Assignee: SEGETIS, INC., Golden Valley, MN 9/04 (2013.01); A61 K 2800/49 (2013.01) (US) USPC .. 424/59: 424/62; 424/65; 514/467: 514/452: 514/159: 424/744: 514/275: 8/416: 8/421; (21) Appl. No.: 14/535,989 8/424; 8/161 (22) Filed: Nov. 7, 2014 (57) ABSTRACT Personal care formulations containing alkyl ketal esters hav Related U.S. Application Data ing the structure (62) Division of application No. 13/104,570, filed on May 10, 2011, now abandoned. I (60) Provisional application No. 61/332,982, filed on May -R 10, 2010, provisional application No. 61/332,978, CH, O filed on May 10, 2010. H2 s CH YO Publication Classification R2 O (51) Int. Cl. CH1 A6 IK 8/49 (2006.01) A61O 15/00 (2006.01) wherein a is 0 or an integer of 1 to 12: b is 0 or 1; R is a A6 IK 8/35 (2006.01) divalent Cls group optionally Substituted with up to 5 A6 IK 8/368 (2006.01) hydroxyl groups; and R' is C, alkyl. US 2015/0064124 A1 Mar. 5, 2015 PERSONAL CARE FORMULATIONS least one of the co-continuous phases is an oil phase; and CONTAINING ALKYL KETAL ESTERS AND wherein any of the foregoing oil phases comprises at least one METHODS OF MANUFACTURE of (a) a paraffinic, naphthenic or aromatic mineral oil, (b) a nonionic organic compound having a melting temperature of CROSS-REFERENCE TO RELATED less than 45°C., a molecular weight of at least 190 Daltons, an APPLICATIONS amido or ester group, and an alkyl chain containing at least 8 0001. This application is a divisional of U.S. Ser. No. carbon atoms, and a solubility in water of no greater than 1 13/104,570, filed May 10, 2011, which claims the benefit of part in 99 parts of water, (c) a nonionic organosilicone com U.S. Provisional Application No. 61/332,978, filed May 10, pound having a melting temperature of less than 45° C., and 2010, and to U.S. Provisional Application No. 61/332,982, a solubility in water of no greater than 1 part in 99 parts of filed May 10, 2010, all of the foregoing being incorporated water, (d) along chain alcohol, or (e) a wax; and (ii) an alkyl ketal ester of structure I. herein by reference in their entirety. 0007. In still another embodiment, a personal care formu FIELD OF THE INVENTION lation comprises an alkyl ketal ester of structure I, and an additional cosmetically acceptable ingredient. 0002 This invention relates to personal care formulations 0008. The invention is further illustrated by the following that contain certain alkyl ketal ester compounds and to meth Detailed Description, Examples, and Claims. ods for the manufacture of the formulations. DETAILED DESCRIPTION BACKGROUND 0009. We have found that certain alkyl ketal esters of 0003 Personal care formulations are available in a wide Structure I are excellent formulatory ingredients that provide range of formulation forms and are used in a wide variety of benefit in a wide number of personal care formulations. The specialized applications. Because these various types of for alkyl ketal esters are excellent solvents for a wide range of mulations differ enormously, as do the conditions under materials, including active agents useful in personal care which they are used, the individual formulations tend to be formulations. Many of them are at least partially miscible formulated specifically for the end-use application for which with water or other organic solvents, or both, as well as a wide they are intended. Further, the use of materials based on range of somewhat hydrophobic materials as are commonly renewable resources is becoming of increasing interest as present in personal care formulations. The alkyl ketal esters formulators redesign their formulations to meet environmen have low volatility. Under normal conditions of manufacture, tal sensitivities of their consumer bases. storage, and use, the alkyl ketal esters are not reactive with many of the other materials that are commonly found in SUMMARY personal care formulations. 0004 Disclosed herein are personal care formulations, the 0010 Because of these attributes, the alkyl ketal esters are personal care formulations comprising an alkyl ketal ester useful in a wide range of personal care formulations, includ having the structure ing formulations that contain various types of active agents as described below, as well as formulations that do not contain Such active agents. The alkylketal esters can provide a range of benefits to the formulation. The particular benefits seen in R1 any given formulation will depend on the particular ingredi CH, O1 ents and function of that formulation. HC1 O 0011. In an embodiment, the alkyl ketal esters of structure CH O I can be used to enhance the solubility of an active agent in a R2 O personal care formulation. Depending on the native solubility CH1 of the active agent in the formulation and the type of formu lation, the alkyl ketal ester can be used as a cosolvent with water, as a compatibilizer with water and an organic solvent, whereina is 0 or an integer of 1 to 12, b is 0 or 1, Radivalent as a cosolvent with an organic solvent, as an emulsifier, or a Cs group optionally substituted with up to 5 hydroxyl combination comprising of any of one or more of the forego groups, and R' is C. alkyl; and an active agent selected from ing. As is known to those of skill in the art of formulating organic anti-aging agents, organic anti-acne agents, organic personal care products, an individual ingredient can have skin whiteners, organic ultraViolet light absorbers, organic more than one type of function, for example a given alkyl tanning agents, organic anti-alopecia agents, antifungal ketal ester could function both as a cosolvent and as a com agents, anti-dandruff active agents, antimicrobial agents, patibilizer. organic medicinals, depilatory compounds, hair dyes, organic 0012. When the active agent has limited water solubility, insect repellants, and combinations thereof. the alkyl ketal ester can in Some embodiments function as a 0005 Also disclosed is a waxy personal care formulation cosolvent, together with water. Many alkyl ketal esters are comprising a wax, an emollient, and an alkyl ketal ester of good solvents for active agents and also have good miscibility structure I. in water. The presence of Such an alkyl ketal ester can allow 0006. In another embodiment, a personal care formulation the concentration of the active agent to be increased, often in the form of an emulsion comprises (i) a continuous phase without the presence of volatile organic compounds (VOCs) and a disperse phase wherein the continuous phase or the Such as ethanol, isopropanol, acetone, ethyl acetate, and the disperse phase is an aqueous phase and the other is an oil like in the formulation. The result in some cases can be a more phase; or at least two co-continuous phases wherein at least concentrated low VOC formulation. The alkyl ketal ester can one of the co-continuous phases is an aqueous phase and at also perform additional functions, such as compatibilization US 2015/0064124 A1 Mar. 5, 2015 of aqueous and organic phases, compatibilization or solubi 0017. Because the alkyl ketal ester is a good solvent for a lization of certain organic materials into an aqueous phase, wide range of materials, it is very useful for making concen emulsification of an oil phase into an aqueous phase or of an trates, which can be let down into water, an alcohol or other aqueous phase into an oil phase. diluent. 0013 The alkyl ketal ester can act as an emulsifier, com 0018 Still another benefit of the alkyl ketal ester in some patibilizer, or solubilizer for ingredients other than the active formulations is that it allows the amount of water to be agent, or as a co-emulsifier, co-compatibilizer, or co-solubi increased in otherwise highly hydrophobic formulations. lizer for ingredients other than the active agent, in particular This can provide a moisturizing function in Some cases, or if the alkyl ketal ester is highly water-soluble. Moreover, provide other benefits. A notable example of this is in lip care incorporation of the alky ketal ester can lead to a lighter, less formulations, particularly lipsticks, lip glosses, and lip balms, greasy or heavy-feeling formulation, especially compared to and cuticle balms which are based on waxes and other highly many other naturally-derived ingredients.
Load more

Recommended publications
  • Regulatory News
    WHO Drug Information Vol. 28, No. 4, 2014 Regulatory news Ebola curative – transfusions of whole blood or blood plasma from recovered patients Update on treatments and vaccines have been scheduled to be conducted in Liberia, in line with WHO technical The Ebola crisis has prompted an guidelines (4). unprecedented cooperation between regulators In September the European Medicines to support WHO and to advise on possible Agency (EMA) established an expert pathways for the development, evaluation and group to review available information approval of medicines to fight Ebola. Progress on Ebola experimental treatments – towards provision of treatments and vaccines is excluding convalescent therapies – and summarized below. invited developers to submit their data (5). In August 2014, a WHO-convened panel Vaccines had agreed unanimously that is ethically On 29–30 September, 70 experts acceptable to use of experimental attended a WHO-convened consultation medicines and vaccines under the on Ebola vaccines. They took stock of the exceptional circumstances of the Ebola many ongoing efforts to rapidly evaluate epidemic (1). In early September, WHO the safety and efficacy of Ebola vaccines convened a consultation on potential for deployment as soon as possible to Ebola therapies and vaccines (2). The critical frontline workers and ultimately to importance of supportive care and populations at risk in mass vaccination community response was stressed in this campaigns. Two candidate vaccines have and subsequent discussions. clinical-grade vials available for safety trials. (6) Treatments In October, WHO convened industry In September, more than 200 experts leaders and key partners to discuss trials from around the world met at WHO and production of Ebola vaccine (7).
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Afamelanotide 16Mg Implant (SCENESSE) for Generalised Vitiligo – First Line in Combination with Narrow-Band Ultraviolet B Light (NB-UVB)
    December Horizon Scanning Research & 2016 Intelligence Centre Afamelanotide 16mg Implant (SCENESSE) for generalised vitiligo – first line in combination with narrow-band ultraviolet B light (NB-UVB) NIHR HSRIC ID: 6667 Lay summary Afamelanotide is a new drug to treat generalised vitiligo. Vitiligo is a long-term condition where white patches develop on the skin, because of a lack of pigment in the skin. This condition may cause significant psychological distress. Afamelanotide is administered as an implant once every 28 days with NB-UVB light therapy administered 2-3 times per week. If licensed, afamelanotide may offer an additional treatment option for patients with this condition. This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. Horizon Scanning Research & Intelligence Centre University of Birmingham [email protected] www.hsric.nihr.ac.uk @OfficialNHSC TARGET GROUP • Generalised vitiligo: adults; stable or slowly progressing; with 10-50% of total body surface involvement – first line; in combination with narrow-band ultraviolet B light (NB- UVB). TECHNOLOGY DESCRIPTION Afamelanotide (SCENESSE; [Nle4,D-Phe7]-alpha-MSH; CUV-1647; EPT-1647; melanotan I; melanotan) is a structural analogue of endogenous alpha-melanocyte-stimulating hormone (α-MSH), which is formulated as a bioresorbable implant.
    [Show full text]
  • Copyrighted Material
    1 Index Note: Page numbers in italics refer to figures, those in bold refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58. A definition 87.2 congenital ichthyoses 65.38–9 differential diagnosis 90.62 A fibres 85.1, 85.2 dermatomyositis association 88.21 discoid lupus erythematosus occupational 90.56–9 α-adrenoceptor agonists 106.8 differential diagnosis 87.5 treatment 89.41 chemical origin 130.10–12 abacavir disease course 87.5 hand eczema treatment 39.18 clinical features 90.58 drug eruptions 31.18 drug-induced 87.4 hidradenitis suppurativa management definition 90.56 HLA allele association 12.5 endocrine disorder skin signs 149.10, 92.10 differential diagnosis 90.57 hypersensitivity 119.6 149.11 keratitis–ichthyosis–deafness syndrome epidemiology 90.58 pharmacological hypersensitivity 31.10– epidemiology 87.3 treatment 65.32 investigations 90.58–9 11 familial 87.4 keratoacanthoma treatment 142.36 management 90.59 ABCA12 gene mutations 65.7 familial partial lipodystrophy neutral lipid storage disease with papular elastorrhexis differential ABCC6 gene mutations 72.27, 72.30 association 74.2 ichthyosis treatment 65.33 diagnosis 96.30 ABCC11 gene mutations 94.16 generalized 87.4 pityriasis rubra pilaris treatment 36.5, penile 111.19 abdominal wall, lymphoedema 105.20–1 genital 111.27 36.6 photodynamic therapy 22.7 ABHD5 gene mutations 65.32 HIV infection 31.12 psoriasis pomade 90.17 abrasions, sports injuries 123.16 investigations 87.5 generalized pustular 35.37 prepubertal 90.59–64 Abrikossoff
    [Show full text]
  • Kaiser Permanente Bernard J. Tyson School of Medicine, Inc. Exclusive Provider Organization (EPO) Student Blanket Health Plan Drug Formulary
    Kaiser Permanente Bernard J. Tyson School of Medicine, Inc. Exclusive Provider Organization (EPO) Student Blanket Health Plan Drug Formulary Effective September 1, 2021 Health Plan Products: Kaiser Permanente Bernard J. Tyson School of Medicine, EPO Student Blanket Health Plan offered by Kaiser Permanente Insurance Company For the most current list of covered medications or for help understanding your KPIC insurance plan benefits, including cost sharing for drugs under the prescription drug benefit and under the medical benefit: Call 1-800-533-1833, TTY 711, Monday through Friday, 7 a.m. to 9 p.m. ET Visit kaiserpermanente.org to: • Find a participating retail pharmacy by ZIP code. • Look up possible lower-cost medication alternatives. • Compare medication pricing and options. • Find an electronic copy of the formulary here. • Get plan coverage information. For cost sharing information for the outpatient prescription drug benefits in your specific plan, please visit kp.org/kpic-websiteTBD The formulary is subject to change and all previous versions of the formulary are no longer in effect. Kaiser Permanente Last updated: September 1, 2021 Table of Contents Informational Section...........................................................................................................................................3 ANTIHISTAMINE DRUGS - Drugs for Allergy.....................................................................................................9 ANTI-INFECTIVE AGENTS - Drugs for Infections...........................................................................................
    [Show full text]
  • WO 2016/195476 Al 8 December 2016 (08.12.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/195476 Al 8 December 2016 (08.12.2016) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/34 (2006.01) A61P 17/16 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL2015/050389 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 29 May 2015 (29.05.2015) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (71) Applicant: ERASMUS UNIVERSITY MEDICAL kind of regional protection available): ARIPO (BW, GH, CENTER ROTTERDAM [NL/NL]; Dr. Molewaterplein GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 50, NL-3015 GE Rotterdam (NL). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: SIJBRANDS, Eric Jacobus Gerardus; c/o Dr.
    [Show full text]
  • Scenesse (Afamelanotide) NOTICE
    DRUG POLICY Scenesse (afamelanotide) NOTICE This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242. BENEFIT APPLICATION Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This policy may not apply to FEP. Benefits are determined by the Federal Employee Program. DESCRIPTION The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. FDA-Approved Indication Scenesse (afamelanotide) is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). POLICY Documentation Requirements Submission of the following information is necessary to initiate the prior authorization review: A.
    [Show full text]
  • The Following Are J Code Requirements
    Updated The following are J Code requirements September 2021 J Codes Auth Required? 20610 - Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) No A9513 - Lutetium Lu 177, dotatate, therapeutic, 1 mCi Yes A9579 - Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (NOS), per ml No C9036 - Injection, patisiran, 0.1 mg Yes C9062 - Injection, daratumumab 10 mg and hyaluronidase-fihj Yes C9064 - Mitomycin pyelocalyceal instillation, 1 mg Yes C9065 - Injection, romidepsin, non-lypohilized (e.g. liquid), 1mg Yes C9066 - Injection, sacituzumab govitecan-hziy, 10 mg Yes C9069 - Injection, belantamab mafodontin-blmf, 0.5 mg Yes C9070 - Injection, tafasitamab-cxix, 2 mg Yes C9071 - Injection, viltolarsen, 10 mg Yes C9072 - Injection, immune globulin (asceniv), 500 mg Yes C9073 - Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Yes C9074 - Injection, lumasiran, 0.5 mg Yes J0129 - Injection, abatacept, 10 mg (code may be used for Medicare when drug administered under the direct supervision of a physician) Yes J0131 - Injection, Acetaminophen, 10 mg No J0133 - Injection, acyclovir, 5 mg No J0150 - Injection, adenosine for therapeutic use, 6 mg (not to be used to report any adenosine phosphate compounds, instead use A9270) No J0171 - Injection, Adrenalin, epinephrine, 0.1 mg No J0178 - Injection, aflibercept, 1 mg No J0485 - Injection,
    [Show full text]
  • Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021 Anatomical Classification Guidelines V2021 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2021 Anatomical Classification Guidelines V2021 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 36 D DERMATOLOGICALS 51 G GENITO-URINARY SYSTEM AND SEX HORMONES 58 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 68 J GENERAL ANTI-INFECTIVES SYSTEMIC 72 K HOSPITAL SOLUTIONS 88 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 96 M MUSCULO-SKELETAL SYSTEM 106 N NERVOUS SYSTEM 111 P PARASITOLOGY 122 R RESPIRATORY SYSTEM 124 S SENSORY ORGANS 136 T DIAGNOSTIC AGENTS 143 V VARIOUS 145 Anatomical Classification Guidelines V2021 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • 2020 Aetna Standard Plan
    Plan for your best health Aetna Standard Plan Aetna.com Aetna is the brand name used for products and services provided by one or more of the Aetna group of subsidiary companies, including Aetna Life Insurance Company and its affiliates (Aetna). Aetna Pharmacy Management refers to an internal business unit of Aetna Health Management, LLC. Aetna Pharmacy Management administers, but does not offer, insure or otherwise underwrite the prescription drug benefits portion of your health plan and has no financial responsibility therefor. 2020 Pharmacy Drug Guide - Aetna Standard Plan Table of Contents INFORMATIONAL SECTION..................................................................................................................6 *ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS* - DRUGS FOR THE NERVOUS SYSTEM.................................................................................................................................16 *ALLERGENIC EXTRACTS/BIOLOGICALS MISC* - BIOLOGICAL AGENTS...............................18 *ALTERNATIVE MEDICINES* - VITAMINS AND MINERALS....................................................... 19 *AMEBICIDES* - DRUGS FOR INFECTIONS.....................................................................................19 *AMINOGLYCOSIDES* - DRUGS FOR INFECTIONS.......................................................................19 *ANALGESICS - ANTI-INFLAMMATORY* - DRUGS FOR PAIN AND FEVER............................19 *ANALGESICS - NONNARCOTIC* - DRUGS FOR PAIN AND FEVER.........................................
    [Show full text]
  • The Management of Seborrheic Dermatitis 2020: an Update
    Review Article The management of seborrheic dermatitis 2020: An update Sandra Widaty1, Kusmarinah Bramono1, Muhammad Yulianto Listiawan2, Ariyati Yosi3, Eliza Miranda1, Githa Rahmayunita1, Herwinda Brahmanti4, Henry W Lim5 1Department of Dermatology and Venereology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia 2Department of Dermatology and Venereology, Faculty of Medicine Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, Indonesia 3Department of Dermatology and Venereology, Faculty of Medicine Universitas Sumatera Utara, H. Adam Malik General Hospital, Medan, Indonesia 4Department of Dermatology and Venereology, Faculty of Medicine Universitas Brawijaya, Dr. Saiful Anwar General Hospital, Malang, Indonesia 5Department of Dermatology, Henry Ford Hospital, Detroit, Michigan, USA Email: [email protected] Abstract Background: Seborrheic dermatitis (SD) is a chronic relapsing dermatitis manifesting in the seborrheic area, affecting infants or adults. In Indonesia, the prevalence of SD is 0.99–5.8% of all dermatology cases from 2013 to 2015. SD has been known to be a prominent manifestation among HIV patients, but there is an increasing trend in the general population. Therefore, in 2017, the Indonesian Society for Dermatology and Venereology proposed a consensus for the management of SD in Indonesia based on the discussion from 12 dermatological centers. Concurrent with the development of new drugs, this study aims to evaluate and develop a guideline for the treatment of seborrheic dermatitis in Indonesia to update the previous guidelines in 2017. Methods: Systematic review was based on evidence-based methods, and scientific evidences were acquired through systematic search. Evidence analysis was in accordance with the level of evidence. The available evidences were evaluated, and conclusion was based on the grade of recommendation.
    [Show full text]
  • Seborrheic Dermatitis and Its Relationship with Malassezia Spp
    REVIEW Seborrheic dermatitis and its relationship with Malassezia spp Manuel Alejandro Salamanca-Córdoba†,1,2, Carolina Alexandra Zambrano-Pérez2,3, Carlos Mejía-Arbeláez2,4, Adriana Motta5, Pedro Jiménez6, Silvia Restrepo-Restrepo7, Adriana Marcela Celis-Ramírez1,8* Abstract Seborrheic dermatitis (SD) is a chronic inflammatory disease that that is difficult to manage and with a high impact on the individual’s quality of life. Besides, it is a multifactorial entity that typically occurs as an inflammatory response toMalassezia species, along with specific triggers that contribute to its pathophysiology. Sin- ce the primary underlying pathogenic mechanisms include Malassezia proliferation and skin inflammation, the most common treatment includes topical antifungal keratolytics and anti-inflammatory agents. However, the consequences of eliminating the yeast population from the skin, the resistance profiles ofMalassezia spp. and the effectivity among different groups of medications are unknown. Thus, in this review, we summarize the current knowledge on the disease´s pathophysio- logy and the role of Malassezia sp. on it, as well as, the different antifungal treatment alternatives, including topical and oral treatment in the management of SD. Key words: seborrheic dermatitis, Malassezia, pathogenic role, treatment. Dermatitis seborreica y su relación con Malassezia spp Resumen La dermatitis seborreica (DS) es una enfermedad inflamatoria crónica, con un elevado impacto en la calidad de vida del individuo. Además, DS es una entidad multifactorial que ocurre como respuesta inflamatoria a las levaduras del género Malassezia spp., junto con factores desencadenantes que contribuyen a la fisio- patología de la enfermedad. Dado que el mecanismo patogénico principal involucra la proliferación e inflamación generada por Malassezia spp., el tratamiento más usado son los agentes tópicos antifúngicos y antiinflamatorios.
    [Show full text]